| Name | Southridge Rehab & Living Ctr |
|---|---|
| Location | 10 May St, Biddeford, Maine |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 78 |
| Occupancy Rate | 69.87% |
| Medicare ID (CCN) | 205136 |
| Legal Business Name | North Country Associates, Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1629138789 |
| Organization Name | NORTH COUNTRY ASSOCIATES, INC |
| Doing Business As | SOUTHRIDGE LIVING CENTER |
| Address | 10 May St, Biddeford, ME 04005 |
| Phone Number | 207-282-4138 |
News Archive
Children who carry variations in specific genes that metabolize vehicle emissions are more susceptible to developing asthma, particularly if they live near major roadways, a study led by researchers at the University of Southern California (USC) suggests.
More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of inhaling vapors, gas, dust or fumes at work, according to a joint American Thoracic Society and the European Respiratory Society statement published in the ATS's American Journal of Respiratory and Critical Care Medicine.
Boehringer Ingelheim and Eli Lilly and Company today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Promethazine Hydrochloride (HCl) Tablets USP, 12.5 mg, 25 mg and 50 mg. Promethazine HCl Tablets are used to relieve the symptoms of certain allergic reactions, such as perennial and seasonal allergic rhinitis.
Now, a new study presented on the preprint server bioRxiv in October 2020 describes the efficient design of an mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on the use of the viral receptor-binding domain (RBD) mRNA encapsulated in lipid nanoparticles (LNP).
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Children who carry variations in specific genes that metabolize vehicle emissions are more susceptible to developing asthma, particularly if they live near major roadways, a study led by researchers at the University of Southern California (USC) suggests.
More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of inhaling vapors, gas, dust or fumes at work, according to a joint American Thoracic Society and the European Respiratory Society statement published in the ATS's American Journal of Respiratory and Critical Care Medicine.
Boehringer Ingelheim and Eli Lilly and Company today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Promethazine Hydrochloride (HCl) Tablets USP, 12.5 mg, 25 mg and 50 mg. Promethazine HCl Tablets are used to relieve the symptoms of certain allergic reactions, such as perennial and seasonal allergic rhinitis.
Now, a new study presented on the preprint server bioRxiv in October 2020 describes the efficient design of an mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on the use of the viral receptor-binding domain (RBD) mRNA encapsulated in lipid nanoparticles (LNP).
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 8.95 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.64 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 48.57 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.45 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.47 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.9 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.47 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.65 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.6 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 19.21 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 81.58 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.12 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.33 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.32 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 87.05 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.68 | 82.93 |
News Archive
Children who carry variations in specific genes that metabolize vehicle emissions are more susceptible to developing asthma, particularly if they live near major roadways, a study led by researchers at the University of Southern California (USC) suggests.
More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of inhaling vapors, gas, dust or fumes at work, according to a joint American Thoracic Society and the European Respiratory Society statement published in the ATS's American Journal of Respiratory and Critical Care Medicine.
Boehringer Ingelheim and Eli Lilly and Company today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Promethazine Hydrochloride (HCl) Tablets USP, 12.5 mg, 25 mg and 50 mg. Promethazine HCl Tablets are used to relieve the symptoms of certain allergic reactions, such as perennial and seasonal allergic rhinitis.
Now, a new study presented on the preprint server bioRxiv in October 2020 describes the efficient design of an mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), based on the use of the viral receptor-binding domain (RBD) mRNA encapsulated in lipid nanoparticles (LNP).
› Verified 4 days ago